Researchers have been excited about the medication , a groundbreaking dual agonist showing remarkable outcomes in early trials for size loss . It functions by targeting both pathways : GLP-1 and GIP, https://anyabozs742552.blogsuperapp.com/41302962/the-new-possibility-for-body-management